Mesoblast (ASX:MSB) - CEO, Silviu Itescu
CEO, Silviu Itescu
Source: Mesoblast
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mesoblast (MSB) receives the green light for a new trial on chronic low back pain due to degenerative disc disease
  • The news follows feedback from the US FDA on the phase three program investigating the use of rexlemestrocel-L in patients with the lower back pain
  • The company says it plans to conduct an additional US phase three trial which may support submissions for potential approval in both the US and Europe
  • If this trial is successful, Mesoblast says it will be eligible to receive payments up to US$112.5 million (A$156.9 million) prior to product launch from its partners in Europe and Latin America
  • Mesoblast is up 11.28 per cent to $1.48 per share as of 11:14 am AEDT

Mesoblast (MSB) has received the green light for a new trial on chronic low back pain due to degenerative disc disease.

The news follows feedback from the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) regarding the phase three program investigating the use of rexlemestrocel-L in patients with the lower back pain.

Rexlemestrocel-L is Mesoblast’s product in development for advanced chronic heart failure and chronic low back pain

The company said it plans to conduct an additional US phase three trial which may support submissions for potential approval in both the US and Europe.

If this trial is successful and leads to European regulatory approval, Mesoblast said it will be eligible to receive payments up to US$112.5 million (around A$156.9 million) prior to product launch from its partner in Europe and Latin America, Grünenthal. This will be inclusive of US$17.5 million (roughly A$24.4) already received.

Following review of the completed trial data, OTAT agreed with Mesoblast’s proposal for pain reduction at 12 months as the primary endpoint of the next trial, with functional improvement and reduction in opioid use as secondary endpoints.

Mesoblast is up 11.28 per cent to $1.48 per share as of 11:14 am AEDT.

MSB by the numbers
More From The Market Herald

" Vital Metals (ASX:VML) to redesign pit at Nechalacho following ore discovery

Vital Metals (ASX:VML) completes maiden mining and ore sorting campaign at its Nechalacho rare earths project…
Brookside Energy (ASX:BRK)- Managing Director, David Prentice

" Brookside Energy (ASX:BRK) sees its quarter revenue skyrocket

Brookside Energy (ASX:BRK) sees its fourth quarter revenue sales skyrocket 800 per cent on quarter to…
Titomic (ASX:TTT) - Incoming Managing Director, Herbert Koeck

" Titomic (ASX:TTT) reshuffles board

Titomic’s (ASX:TTT) Chief Executive Officer, Herbert Koeck has been appointed Managing Director of the company.
Dreadnought Resources (ASX:DRE) - Managing Director, Dean Tuck

" Dreadnought Resources (ASX:DRE) reports delays in results as activity ramps up

Dreadnought Resources (ASX:DRE) said certain results have been delayed until February due to industry-wide obstructions.